ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SN. Smith & Nephew Plc

978.80
-3.80 (-0.39%)
24 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew Plc LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.80 -0.39% 978.80 975.80 976.20 983.80 967.80 975.60 3,092,529 16:35:08
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Ortho,prosth,surg Appl,suply 5.55B 263M 0.3011 32.41 8.52B
Smith & Nephew Plc is listed in the Ortho,prosth,surg Appl,suply sector of the London Stock Exchange with ticker SN.. The last closing price for Smith & Nephew was 982.60p. Over the last year, Smith & Nephew shares have traded in a share price range of 887.00p to 1,269.00p.

Smith & Nephew currently has 873,398,889 shares in issue. The market capitalisation of Smith & Nephew is £8.52 billion. Smith & Nephew has a price to earnings ratio (PE ratio) of 32.41.

Smith & Nephew Share Discussion Threads

Showing 1226 to 1249 of 1325 messages
Chat Pages: 53  52  51  50  49  48  47  46  45  44  43  42  Older
DateSubjectAuthorDiscuss
13/10/2023
10:33
trading update for the period ended 30 September 2023 on Thursday, 2 November 2023 at 7.00am GMT / 3.00am EDT. This will be followed by a conference call for financial analysts at 8.30am GMT / 4.30am EDT, details of which will be published on the Smith+Nephew website at

Enquiries

pugugly
12/10/2023
15:48
He did indeed, trading margin at a smidge over 26% was the peak on that score.

On outsourcing, I completely missed the MTO turnaround, a tad annoying as
know the business well.

essentialinvestor
12/10/2023
15:36
2010 seems to be the peak year with a trading profit of 969k and a margin of 24.4% compared to 2022 with 901k trading profit and a margin of 17.2%. Rupert Soames did a good job of sorting out Serco so hopefully he can make a difference now he is chairman here. By mid 2014 share price was £11 despite profits reducing from 2010 onwards.
lonrho
12/10/2023
14:58
Laurence, part of the issue is arguably their main competitors growing stronger
v SN over the last decade. This may account for some of SN's weaker metrics.

While a bid can't be ruled out, it has been mentioned as a takeover candidate for decades.

If you go back 10 years, this was a high margin business with low gearing and
a prodigious cash generator. Those bullish on SN may say that's now reflected in
the current share price, however circa 2013, at approx £8 plus a share you were
buying at the time a great business.

essentialinvestor
12/10/2023
09:35
#Essential Investor - thanks, historic margin loss is why the company is on a 10 year low, I am looking for reasons why it may have bottomed out and offer growth going forward up from the 15.3% margin from H1, in an attempt to establish if this is a reasonable entry point...

2023 FY outlook - increased full year underlying revenue growth guidance of 6.0% to 7.0% (previously 5.0% to 6.0%), unchanged trading profit margin guidance, expected to be at least 17.5%..

Debt interest will be close to peaking out soon and could subside from 2024 impacting all indebted companies..

laurence llewelyn binliner
12/10/2023
09:01
How are margins stable?, trading profit margin registered a hefty fall at the H1 to
15.3%.

For years SN had trading profit margins in excess of 20%, for a few years around 24/25%.

Margins began a multi year decline around 2015/16 (from memory)
and despite multiple CEO's since, each with a new refreshed strategy
to improve business performance, results have arguably been sadly lacking.


Margin compression leading to reduced free cash flow is central to the bearish case on SN.

essentialinvestor
12/10/2023
08:00
A lot more research to do yet, but revenues are +, margins stable, the 12 step recovery program on track, but debt was up USD350M in H1 and the CFO is off summer 2024..
laurence llewelyn binliner
11/10/2023
21:02
Seems to be following Stryker down which was off 5% today. I can tell you the weight loss drugs driven sell off is absolute nonsense. If you are in the medical profession you will understand why.
justiceforthemany
11/10/2023
20:43
Citadel to blame here.
Ludicrous valuation.
Debt is NOT an issue.

justiceforthemany
11/10/2023
19:22
LLB Most useful post - Had been considering but given you clarification on debt will lower gamble target.
pugugly
11/10/2023
19:13
New potential investor here looking in at opportunity..

No more dividends until May 2024 and sitting at a 10 year low SP, is there much to prop this share up and drive a turnaround growth story..?

Or is it all down to the debt pile hurting much like everything else in the red..?

03.08.2023 - The net interest charge within reported results was USD44M, with the change due to an increase in net debt year on year and an increase in the overall weighted average interest rate given the prevailing higher rate environment. The groups net debt excluding lease liabilities, increased from USD2.3BN at 31 December 2022 to USD2.65BN at 1 July 2023 with committed facilities of USD3.7BN
We expect to finish 2023 with leverage of 2.0x, unchanged year-on-year.

2023 FY outlook - increased full year underlying revenue growth guidance of 6.0% to 7.0% (previously 5.0% to 6.0%) unchanged trading profit margin guidance, expected to be at least 17.5%

laurence llewelyn binliner
11/10/2023
15:15
Stryker do not need SN, while you can't rule a bid out I would be surprised to see one from Stryker.
essentialinvestor
11/10/2023
15:07
Yep - not looking good.
Suet

suetballs
11/10/2023
14:43
at these levels they need to be swallowed up by stryker.
edwardt
05/10/2023
15:24
Yes it is but even on an up day this is down.
Deepak Nath must go!
Be sacked or resign. Awful CEO.

justiceforthemany
05/10/2023
08:27
Ex Dividend today - 11.915p
pugugly
04/10/2023
15:24
So many FTSE stocks trading at decade lows. Are things really that bad? Elections loom and if a recession is truly here then rates will simply HAVE to be cut.
justiceforthemany
28/9/2023
15:12
Company seems to be acutely aware of that EI. New Chairman in Soames, recent board/director shake up also. Deepak needs a good hard slap. Would not take much to get this company growing again now that lockdowns are behind us. 100% upside just to get back to pre Covid highs.
justiceforthemany
28/9/2023
14:51
Stryker up 3%
justiceforthemany
28/9/2023
13:39
With respect this is company specific, nothing to do with some new drug.
essentialinvestor
28/9/2023
13:38
Is the company worth HALF what it was pre pandemic?
Of course not.
Surprised no one has snapped this up. Bargain. Weak pound to boot.

justiceforthemany
28/9/2023
13:37
That is completely overblown - obesity is a growing problem and these are no miracle cures for this issue - and this company is very well diversified not just relying on joint replacements. Ridiculous.
justiceforthemany
27/9/2023
21:08
The concern seems to be obesity drugs leading to fewer fatties needed knee and hip replacements
smcni1968
27/9/2023
21:01
Margin compression is what analysts are fretting about, frequent CEO changes,
each with a new plan to improve efficiency and drive growth.

essentialinvestor
Chat Pages: 53  52  51  50  49  48  47  46  45  44  43  42  Older

Your Recent History

Delayed Upgrade Clock